+44 (0) 20 3997 7634 | sales@fbkmed.com

Gray matter textural heterogeneity as a potential in-vivo biomarker of fine structural abnormalities in Asperger syndrome.

Home > Gray matter textural heterogeneity as a potential in-vivo biomarker of fine structural abnormalities in Asperger syndrome.

Gray matter textural heterogeneity as a potential in-vivo biomarker of fine structural abnormalities in Asperger syndrome.

13/02/13

Latest Articles

Interim results for the six months ended 30 November 2022

07/02/23

Bleepa Feedback Medical Feedback PLC

Annual Results: New strategic direction delivers growth in Bleepa sales

20/09/22

Bleepa Feedback Medical Feedback PLC

Feedback awarded 12-month contract for pilot extension in Sussex CDC

06/09/22

Bleepa Feedback Medical Feedback PLC